A5102870552- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- HER2/EGFR in Cancer Research
- Esophageal Cancer Research and Treatment
- Breast Lesions and Carcinomas
- Cancer Genomics and Diagnostics
- Breast Implant and Reconstruction
- Cancer Diagnosis and Treatment
- Medical Imaging Techniques and Applications
- Ferroptosis and cancer prognosis
- Global Cancer Incidence and Screening
- Lung Cancer Treatments and Mutations
- Reproductive Health and Contraception
- Cancer Cells and Metastasis
- Radiomics and Machine Learning in Medical Imaging
- Nonmelanoma Skin Cancer Studies
- Pregnancy and Medication Impact
- BRCA gene mutations in cancer
- PARP inhibition in cancer therapy
- Immunotherapy and Immune Responses
- Cancer Risks and Factors
- Histone Deacetylase Inhibitors Research
Essen University Hospital
2021-2024
Bochum University of Applied Sciences
2024
Klinik für Frauenheilkunde
2022-2024
Hochschule für Gesundheit - University of Applied Sciences
2024
Charité - Universitätsmedizin Berlin
2019-2022
Olgahospital
2020
The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents 2024 update evidence-based recommendations for diagnosis and treatment patients with locally advanced metastatic breast cancer.
The rapid increase in knowledge tumour biology and pathogenesis of triple-negative breast cancer (TNBC) has resulted new therapeutic approaches concepts for treatment. For years, TNBC been considered to be a difficult-to-treat due its generally aggressive view limited options. risk recurrence metastasis is higher than the case other subtypes same stage. In addition surgery radiation curative situation, systemic chemotherapy with anthracyclines and/or taxanes still therapy choice. New are...
Higher density of stromal tumor-infiltrating lymphocytes (sTILs) at baseline has been associated with increased rates pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC). While evidence supports favorable association pCR survival TNBC, an independent impact sTILs (after adjustment for pCR) on is not yet established. Moreover, the sTIL dynamics during NACT and TNBC unknown.
For many decades, the standard procedure to treat breast cancer included complete dissection of axillary lymph nodes. The aim was determine histological node status, which then used as basis for adjuvant therapy, and ensure locoregional tumour control. In addition debate on how optimise therapeutic strategies systemic treatment radiotherapy, current discussion focuses improving surgical procedures cancer. As neoadjuvant chemotherapy is becoming increasingly important, cancer, whether they...
The results of the international St. Gallen Consensus Conference for treatment patients with primary breast cancer were discussed this year by a working group leading experts in view therapy recommendations everyday clinical practice Germany. Three are also members year's panel. comparison annually updated AGO 2019 as well S3 guideline is useful, since panel represent opinions from various countries and disciplines. based on evidence-based research literature. This 16th conference featured...
The presence of tumor-infiltrating lymphocytes has been associated with prognosis and chemotherapy response, particularly in high-risk breast cancer subtypes. There is limited data so far as to (i) how lymphocyte (TIL) measurements correlate genomic such the Oncotype DX Recurrence Score® (ii) whether survival impact TIL varies according different adjuvant systemic therapies. WSG PlanB trial compared an anthracycline-free regimen (6x docetaxel/cyclophosphamide, TC) anthracycline-taxane...
Aim: Breast cancer is a heterogeneous disease with distinct molecular and clinical behavior demanding reliable biomarkers, especially in triple-negative breast (TNBC). This study seeks to improve the understanding of SFRP1 as potential biomarker focusing on TNBC. Materials & methods: expression was investigated via immunohistochemistry two anti-SFRP1-antibodies tissue-microarrays 376 invasive cancers. Results: Statistical analysis revealed highly significant association between TNBC (n = 36)...
Abstract Introduction: Improvement of systemic treatment TNBC represents an unmet medical need. Targeted therapy regulatory immune pathways has become important option in the many malignant diseases including breast cancer. Neodjuvant trials combining chemotherapy and checkpoint inhibitors (KEYNOTE-522 IMpassion031) have demonstrated a meaningful benefit regarding pathological complete remission (pCR) for addition PD-1- or PD-L1-inhibitors to patients with TNBC. In KEYNOTE-522 trial,...
595 Background: neoMono randomized patients (pts) with triple negative breast cancer (TNBC) to receive (Arm A) or not B) 2-week Atezolizumab monotherapy prior neoadjuvant 24-week + chemotherapy. In prespecified interim analysis, no difference regarding pathological complete response (pCR) was observed among all pts. However, in regard pCR rates, pts PD-L1 positive TNBC seem benefit from addition of the window. Here we analyze association between central TILs and Ki-67 at baseline (BL) /...
Abstract Background: Immunotherapy, mainly by the use of immune checkpoint inhibitors (ICI), has been established as a standard option for both, solid tumors and hematological malignancies. Unfortunately, this success only replicated in subset patients (pts) with gynecological cancers. In ovarian cancer (OC), response rates to ICI monotherapy were low breast (BC), subgroup triple-negative BC (TNBC) pts showed an improved outcome addition ICI. One reason limited immunotherapy might be...
Abstract HER2DX genomic assay in triple-negative breast cancer (TNBC) patients treated with 12-weeks of neoadjuvant chemotherapy: a correlative analysis from WSG-ADAPT-TN phase II trial Background: Biomarkers for de-escalation and escalation systemic therapy early-stage TNBC are needed. is standardized prognostic (risk-score) predictive (pathological complete response [pCR]-score) based on clinical gene expression-based data. Here we aimed to test the value early TNBC. Methods: Standardized...
Background/Aim: Targeted intraoperative radiotherapy (TARGIT IORT) is an option during breast-conserving surgery (BCS). No data have yet been published regarding the safety of TARGIT IORT with implants in situ. attractive this context because risk capsular fibrosis following external beam (EBRT) such patients. Patients and Methods: We are reporting a retrospective analysis 16 patients who received BCS for early breast cancer after previous implant-based augmentation. was performed using...
<div>AbstractPurpose:<p>Although optimal treatment in early triple-negative breast cancer (TNBC) remains unclear, de-escalated chemotherapy appears to be an option selected patients within this aggressive subtype. Previous studies have identified several pro-immune factors as prognostic markers TNBC, but their predictive impact regarding different strategies is still controversial.</p>Experimental Design:<p>ADAPT-TN a randomized neoadjuvant multicenter phase II trial...
Abstract Background: Among patients with highly heterogeneous HER2+ breast cancer (BC), pathological complete response (pCR) (ypT0/is/ypN0) is associated improved prognosis. The prospective, phase-II neoadjuvant 3-arm WSG HER2+/HR+ trial (ADAPT-TP) showed pCR rates of about 41.0% after 4xT-DM1+/-ET and 15% trastuzumab+ET. Pre-planned translational analysis ADAPT-TP has revealed several biomarkers impact on pCR, such as PIK3CA mutation status, HER2-enriched subtype (by PAM50), Bcl-2 most...
The most important goal of treatment patients with metastatic breast cancer is maintenance or even improvement quality life. In this setting, chemotherapy should be used as much restraint possible. If palliative indicated, the taxane drug class an established option. updated guidelines Gynaecological Oncology Working Group (AGO), Breast Committee, German Society for Gynaecology and Obstetrics (DGGG) Cancer e. V. (DKG) provide recommendations greatest possible evidence on which licensed...